The most prevalent TRAEs associated with PD-1/L1 dual immunotherapy included hypertension, proteinuria, lipase level increased, diarrhea, fatigue, rash maculopapular, anemia, peripheral neuropathy and neutropenia. This evidence concerns the gene PDCD1 and anemia (phenotype).